Blair William & Co. IL lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 15.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,070,763 shares of the company’s stock after purchasing an additional 142,493 shares during the quarter. Blair William & Co. IL’s holdings in Johnson & Johnson were worth $176,398,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Solstein Capital LLC purchased a new stake in shares of Johnson & Johnson during the first quarter worth approximately $30,000. Newton One Investments LLC purchased a new position in Johnson & Johnson in the second quarter worth $31,000. Annapolis Financial Services LLC raised its position in Johnson & Johnson by 109.4% in the second quarter. Annapolis Financial Services LLC now owns 312 shares of the company’s stock worth $51,000 after acquiring an additional 163 shares in the last quarter. Lake Point Wealth Management purchased a new position in Johnson & Johnson in the second quarter worth $52,000. Finally, Cypress Point Wealth Management LLC purchased a new position in Johnson & Johnson in the second quarter worth $58,000. Institutional investors and hedge funds own 67.29% of the company’s stock.
JNJ has been the subject of several research analyst reports. Credit Suisse Group set a $193.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, June 7th. SVB Leerink reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Thursday, July 29th. Finally, Morgan Stanley cut Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a research report on Tuesday, September 7th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $190.38.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.29 by $0.19. Johnson & Johnson had a net margin of 19.92% and a return on equity of 37.06%. The firm had revenue of $23.31 billion during the quarter, compared to the consensus estimate of $22.54 billion. During the same period last year, the firm posted $1.67 EPS. The firm’s revenue for the quarter was up 27.1% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 9.65 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th were issued a dividend of $1.06 per share. The ex-dividend date of this dividend was Monday, August 23rd. This represents a $4.24 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 52.80%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Article: What are popular green investing opportunities?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.